All Posts

The Hard Pivot: What happens after a biotech reboots?

Jan 27, 2026

•

11 min read

The $2m Oversight: Don't forget to Exercise

Jan 23, 2026

•

5 min read

Big Volume, Boring News: Why Stocks Move on “Nothing”

Jan 22, 2026

•

9 min read

Explained: Why Options Magnify Risk and Reward

Jan 21, 2026

•

12 min read

Whale Watching: What is driving the share price?

Jan 20, 2026

•

10 min read

Playing the Catalysts: The Cynata (ASX: CYP) Story

Jan 19, 2026

•

13 min read

The Cannabis Merger Trade: Liquidity First, Value Later

Jan 16, 2026

•

11 min read

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jan 15, 2026

•

11 min read

The Art of the Capital Raise

Jan 14, 2026

•

7 min read

The Problem With Being the Best Stock in the Market

Jan 13, 2026

•

9 min read

What happens when pharma’s biggest accidental blockbuster comes off patent?

Jan 12, 2026

•

9 min read

Biotech’s biggest week starts as the M&A window opens

Jan 9, 2026

•

7 min read

1...8 9 10 11 12

All Posts

The Hard Pivot: What happens after a biotech reboots?

The $2m Oversight: Don't forget to Exercise

Big Volume, Boring News: Why Stocks Move on “Nothing”

Explained: Why Options Magnify Risk and Reward

Whale Watching: What is driving the share price?

Playing the Catalysts: The Cynata (ASX: CYP) Story

The Cannabis Merger Trade: Liquidity First, Value Later

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

The Art of the Capital Raise

The Problem With Being the Best Stock in the Market

What happens when pharma’s biggest accidental blockbuster comes off patent?

Biotech’s biggest week starts as the M&A window opens

The Armchair Analyst